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histopathological types. On immunostaining expression pattern of CK 
in large cell carcinoma was similar to that of adenocarcinoma.
Conclusion: The investigations of CK expression give us additional 
information concerning histopathological differentiation of primary 
lung cancer. Though more investigations are needed, there is a strong 
possibility that classiﬁcation based upon proteomic analysis, as well 
as morphological features, may reﬂect the biological characteristics of 
tumor cells.
P2-060 BSTB: Others Posters, Tue, Sept 4 
Altered iron metabolism, inflammation, transferrin receptors and 
ferritin expression in lung cancer
Kukulj, Suzana 
Clinical Hospital For Lung Diseases Jordanovac, Zagreb, Croatia
Introduction: Alterations in whole-body iron metabolism are known 
to occur in patients with cancer. Iron could participate in carcinogenesis 
and overabundance of iron is associated with increased risk of neopla-
sia at the site of metal deposition. 
Aim: The relationship between the iron status and survival of lung 
cancer patients and the expression of transferrin receptors 1 (TfR1) and 
ferritin in tumor tissue, tumor stroma and normal lung were studied. 
Patients and Methods: These ﬁndings were correlated with tumor 
type and clinical outcome in 111 male patients. Iron metabolism and 
inﬂammation parameters were determined by automated laboratory 
measurements at the time of diagnosis. TfR1 and ferritin expression 
were determined by immuno-histochemical methods on cancer tissue, 
tumor stroma and on the surrounding normal lung tissue. 
Results: More than ﬁfty percentages of patients survived less than 12 
months. At the time of diagnosis approximately a half of the patients 
had mild anemia of chronic disease and signiﬁcantly elevated serum 
ferritin. Nonspeciﬁc laboratory markers of inﬂammation were present. 
Tumor tissue expressed much more TfR1 and ferritin than the tumor 
stroma and normal lung tissue. The expression of TfR1 and the ferritin 
content in tumor tissue depended on the carcinoma type. TfR1 and the 
ferritin content in tumor tissue did not show correlation with systemic 
parameters of most of iron metabolism parameters. Strong ferritin ex-
pression in tumor tissue correlates only with lower transferin saturation.
Conclusion: Higher expression of ferritin in tumor tissue is not the re-
sults of higher body iron accumulation. Elevated serum ferritin in lung 
cancer patients is results of inﬂammation and oxidative stress rather 
than body iron overload. 
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Introduction: For some years, NSE has been known as a marker of 
choice for small cell lung cancer. However, its diagnostic sensitivity 
and speciﬁcity are not completly satisfactory, due to relatively high 
false negative rate in SCLC patients with limited disease and false posi-
tive rate in patients with non-malignant lung disease and non-small cell 
lung cancer. Recently, the usefulness of pro-gastrin-releasing peptide 
(ProGRP) as a tumor marker for SCLC has been investigated. Although 
the diagnostic sensitivity and speciﬁcity of ProGRP was found to be 
higher than serum NSE, only small number of data concern its utility 
in disease therapy monitoring and its value in prediction of response 
to treatment. The aim of the study was the evalutation of ProGRP and 
NSE levels at the time of diagnosis and during chemo- and radiothera-
py of SCLC patients with limited disease in respect to their prognosis.
Material and Methods: Studies of NSE and ProGRP were performed 
in a group of 52 SCLC-LD. Patients with SCLC with limited disease 
were treated simultaneously with chemo and radiotherapy. All of them 
also received prophylactic cranial irradiation between fourth and ﬁfth 
course of chemotherapy. The increment ratio of tumor markers was 
calculated as serum concentration divided by the cut off, for assessment 
of prognostic value of these markers.
Results: ROC curve analysis conﬁrmed that ProGRP was a better than 
NSE tumor marker for diagnostics of SCLC-LD patients ( Area under 
curves ROC: 0.935 vs. 0.789, p = 0.000). 
There were observed signiﬁcant differences in the frequency of 
elevated NSE and ProGRP levels before each course of chemotherapy 
and 3 months after its ﬁnishing, respectively:1st 57.6% vs. 78.8%, 2nd 
5.8% vs. 67.3%, 3th 0% vs. 36.5%, 4th 1.9% vs. 21.2%, in restaging 
6.7% vs. 15.7%. Changes in NSE levels during therapy were more in-
tensive than for ProGRP what was reﬂected in tumor markers half-life 
(NSE: 4.6 - 11 days; ProGRP: 19-28 days) as well as in the frequency 
of increment of tumor markers ratio values. Patients with tumor marker 
levels 2 times exceeding NSE cut off and 12.5-times ProGRP cut off 
before treatment, and those with NSE and ProGRP having these ratio 
values higher than 0.4 and 0.65 during restaging 3 months after ﬁnish-
ing therapy has shown worse prognosis. 
Multivariate analysis conﬁrmed that independent prognostic factors in 
SCLC with limited disease were: NSE level exceeding 2-times cut off 
value before treatment as well as NSE threshold 0.4 cut off and 0.65 
ProGRP cut off value 3 months after therapy.
Conclusions: 
1 Changes of ProGRP during combined therapy of SCLC-LD seem to 
be more adequate to actual clinical status of patients than NSE
2. NSE before treatment is a better than ProGRP prognostic factor in 
SCLC-LD patients however after ﬁnishing therapy both markers 
have similar predictive value
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Background: Low levels of circulating cell-free DNA are present in 
normal individuals. In cancer patients, much higher levels of circulating 
DNA are found. Importantly, circulating DNA in lung cancer patients 
demonstrates genetic alterations typical of the tumour, leading to interest 
in plasma and serum DNA for early clinical diagnosis, prognosis and 
disease monitoring. There is considerable variation among studies in the 
reported levels of circulating DNA and its characteristics, which may be 
attributable to differences in selection of the patient and control groups, 
and the methods used for DNA extraction and estimation of circulating 
DNA concentrations. Here, we compare the efﬁciency of different meth-
ods for extracting low-level circulating DNA from blood samples.
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Methods: Blood, plasma and serum samples were spiked with known 
quantities of human DNA. To optimize the yield of DNA, we inves-
tigated the effects of changes in the blood collection and process-
ing, storage and DNA extraction protocols. We compared two DNA 
puriﬁcation methods, the QIAamp blood DNA kit (QIAGEN) (with 
and without proteinase K pre-digestion) and phenol/chloroform DNA 
extraction after heat denaturation (5 minutes at 95˚C). Extracted DNA 
was quantiﬁed using the PicoGreen assay and its quality was checked 
by conventional PCR analysis for the p53 gene. 
Results: Using the standard QIAamp protocol, the efﬁciency of DNA 
extraction from serum was 13.8 ± 5.9% (Mean ± SD). Pre-incubation 
with proteinase K (0.4 mg/ml, QIAGEN) at 37˚C for 2 hours signiﬁcant-
ly increased the DNA recovery (p<0.0001, unpaired t-test), but longer 
incubation time and incubation at 50˚C did not improve the DNA yield 
further. Further improvements in the efﬁciency of the QIAamp protocol 
were obtained by increasing the volume of elution buffer, but reloading 
the columns and using different buffers did not improve the yield. Using 
the phenol/chloroform extraction method after heat denaturation, the ef-
ﬁciency of DNA extraction was 52.7 ± 4.6% (Mean ± SD), which is sig-
niﬁcantly better than the QIAamp protocol (p<0.0001, unpaired t-test). 
Delays in processing blood samples reduced the DNA yield. Importantly, 
all the recovered DNA was of quality suitable for PCR analysis.
Conclusions: We recommend that blood samples are held on ice for 
no more than 1 hour before plasma/serum separation by double spin. 
Because of its higher efﬁciency, low-cost and good quality products for 
PCR analysis, we prefer the phenol/chloroform circulating DNA isola-
tion method with heat denaturation. 
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Background: Previous studies have shown pre and post-operative 
serum carcinoembryonic antigen (CEA) levels are a prognostic factor 
in patients with non-small cell lung cancer (NSCLC). We prospectively 
investigated the clinical and prognostic signiﬁcance of serum CEA 
elevation as well as the clinical and pathological characteristics in 
patients with stage IIIB and IV NSCLC. 
Methods: From March 2005 to January 2007, 308 patients with IIIB 
and IV stage NSCLC were included. Several chemotherapy proto-
cols including gemcitabine, vinorelbine or paclitaxel combined with 
cisplatin, carboplatin, or erlotinib were used. Serum CEA levels were 
obtained before and after 2 cycles of treatment. Stage was determined 
by CT and bone scans. 
Results: One hundred twenty patients had brain CT scan at diagnosis 
due to neurological symptoms. Twenty eight per cent had stage IIIB, 
and 61.4% stage IV disease. Eighteen per cent had CNS metastases at 
the time of diagnosis. Histological type was adenocarcinoma in 69.1% 
and squamous in 30.9%. Mean serum CEA concentration was 11.3 ng/
ml ± 24.5 with a median of 6.7 (range 0.2 to 4578). Patients with CEA 
levels > 10, 20, 50 and 100 were 43.6, 32.5, 24 and 17.9%; respec-
tively. Associated factors with CEA >20 were age >62 (p=0.02), stage 
IV (p=0.05), CNS metastases (p=0.0001) and histologic type (p=0.01). 
However, logistic regression analysis showed the only associated fac-
tors were histologic type (p=0.0001) and CNS metastases (p=0.0001). 
Patients with CEA elevation >20 had a hazard ratio of 26.3 (CI 11.2 to 
61.6) for the development of brain metastases. Overall survival associ-
ated factors included poor status performance (p=0.006), tobacco use 
(p=0.05), CEA elevation (p=0.0022), CNS metastases (p=0.0157), and 
male gender (p=0.08). There were no differences between stages (IIIB 
vs. IV) and hepatic metastases. The associated factors with survival by 
Cox proportional hazards regression multivariate analysis were poor 
performance status (p=0.05) and CEA elevation (p=0.008). The inde-
pendent factors associated with CEA elevation were adenocarcinoma 
histologic type and brain metastases. 
Conclusions: Patients with stage IIIB and IV NSCLC and with serum 
CEA >20 without neurological symptoms could beneﬁt from early CT 
brain scan. In this group of patients, the most important independent 
factors for survival were poor performance status and CEA elevation.
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The aim of this study was to assess the prognostic impact on survival of 
Cyfra 21-1, CEA and NSE in NSCLC pts receiving complete resec-
tion. Eight-hundred and twenty nine pts with histologically proven 
NSCLC stage I-IIIA receiving complete resection were included (stage 
I- 381; stage II- 212; stage IIIA - 227). The serum levels of all mark-
ers were measured using commercially available immunoassays and 
were obtained immediately before surgery. With a medium follow-up 
of 88 months, patients with initial Cyfra 21-1 higher than 3.3 ng/ml 
had a very signiﬁcant worse prognosis (p<.00001). Higher than 9.8 
ng/ml baseline CEA showed also a bad prognostic impact, but only for 
adenocarcinoma (p=0.0023). NSE showed no prognostic importance. 
In a Cox regression model, Cyfra 21-1 proved to be, among 25 other 
usual independent factors, the strongest independent prognostic factor 
for both overall survival and disease-free interval. In fact, the overall 
5-years survival-rate for all pts in stage I was 54.3%, but increase to 
75.7% in the 268 pts (70.3%) with normal baseline Cyfra 21-1 and 
strongly decrease to less than 15% for the 113 pts (29.7%) with higher 
than 3.3 ng/ml baseline Cyfra 21-1 levels. Very similar results were ob-
tained with stage II and IIIA pts and were presented in our communica-
tion. For those pts with higher Cyfra 21-1 values adjuvant (used in 248 
pts) and particularly neo-adjuvant chemotherapy (used in 88 pts) seems 
to reduce clearly these critical survival results. Survival comparisons 
will be presented in detail. 
